Schrodinger Inc Aktie News

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 14, 2025, the company granted restricted stock units (RSUs) with respect to 1,666 shares of the company's common stock to four newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of direct...

Schrödinger, Inc. (NASDAQ:SDGR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 11:30 AM EDT Company Participants Ramy Farid - CEO, President & Director Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Richie Jain - Executive VP, CFO & Treasurer Conference Call Participants Sean Laaman - Morgan Stanley, Research Division ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference. The live presentation will take place on Monday, September 8, 2025 at 11:30 a.m. E.T. The live webcast can be accessed in the “Investors” section of Schrödinger's website and will be archived for approxima...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors ...

NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1...

Schrödinger, Inc. (NASDAQ:SDGR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jaren Irene Madden - Chief Corporate Affairs Officer & Head of Investor Relations Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Ramy Farid - CEO, President & Director Richie Jain - Executive VP, CFO & Treasurer Conference Call Partici...

Image source: The Motley Fool.

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced financial results for the quarter ended June 30, 2025.